Abstract
The human malarial parasite, Plasmodium falciparum, is responsible for one of the most infectious diseases of the world and is quickly gaining resistance to the commonly used antimalarial treatments. New data are continually reinforcing the idea that biological functions associated with the ubiquitin proteasome system (UPS) are not just limited to non-lysomal degradation of proteins but consist of a wide array of regulatory mechanisms such as cell cycle progression, transcriptional regulation, gene expression and trafficking. While there is much effort in understanding the UPS in many eukaryotic organisms, the Plasmodium UPS has been relatively understudied despite its potential as a therapeutic drug target. However, in vitro proteasome inhibitors studies have confirmed the essentiality of the UPS in Plasmodia with limited toxicity to human cell lines. In addition, computational studies have shown that there are a number of ubiquitinating proteins upstream of the proteasome that may serve as parasite-specific drug targets due to their variety and divergences from other eukaryotic species. In this review, we highlight the major findings about Plasmodiums UPS and discuss its possible implications as an effective and specific antimalarial target.
Keywords: Plasmodium falciparum, ubiquitin proteasome system, drug discovery, ubiquitin-ligase, malaria
Infectious Disorders - Drug Targets
Title: Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future
Volume: 10 Issue: 3
Author(s): Duk-Won Doug Chung and Karine G. Le Roch
Affiliation:
Keywords: Plasmodium falciparum, ubiquitin proteasome system, drug discovery, ubiquitin-ligase, malaria
Abstract: The human malarial parasite, Plasmodium falciparum, is responsible for one of the most infectious diseases of the world and is quickly gaining resistance to the commonly used antimalarial treatments. New data are continually reinforcing the idea that biological functions associated with the ubiquitin proteasome system (UPS) are not just limited to non-lysomal degradation of proteins but consist of a wide array of regulatory mechanisms such as cell cycle progression, transcriptional regulation, gene expression and trafficking. While there is much effort in understanding the UPS in many eukaryotic organisms, the Plasmodium UPS has been relatively understudied despite its potential as a therapeutic drug target. However, in vitro proteasome inhibitors studies have confirmed the essentiality of the UPS in Plasmodia with limited toxicity to human cell lines. In addition, computational studies have shown that there are a number of ubiquitinating proteins upstream of the proteasome that may serve as parasite-specific drug targets due to their variety and divergences from other eukaryotic species. In this review, we highlight the major findings about Plasmodiums UPS and discuss its possible implications as an effective and specific antimalarial target.
Export Options
About this article
Cite this article as:
Doug Chung Duk-Won and G. Le Roch Karine, Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future, Infectious Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187152610791163345
DOI https://dx.doi.org/10.2174/187152610791163345 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Evaluation of an Ectopic Supernumerary Kidney in Pelvis
Current Medical Imaging Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging
Anti-Cancer Agents in Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Development of 5-Fluorouracil Derivatives as Anticancer Agents
Current Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Dendritic Cell Immunotherapy for Malignant Gliomas
Reviews on Recent Clinical Trials Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design The Hedgehog Knows Many Tricks
Current Drug Targets Keratin-Based Biomaterials for Biomedical Applications
Current Drug Targets Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy
Current Drug Targets Phenolic Composition, Antioxidant and Cytotoxic Prospective of three Linum species: A Potential Source of Novel Anticancer Pharmacophores
Current Organic Chemistry Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets